These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures. Nowotarski SL; Pachaiyappan B; Holshouser SL; Kutz CJ; Li Y; Huang Y; Sharma SK; Casero RA; Woster PM Bioorg Med Chem; 2015 Apr; 23(7):1601-12. PubMed ID: 25725609 [TBL] [Abstract][Full Text] [Related]
4. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Murray-Stewart T; Woster PM; Casero RA Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577 [TBL] [Abstract][Full Text] [Related]
5. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Huang Y; Stewart TM; Wu Y; Baylin SB; Marton LJ; Perkins B; Jones RJ; Woster PM; Casero RA Clin Cancer Res; 2009 Dec; 15(23):7217-28. PubMed ID: 19934284 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Huang Y; Greene E; Murray Stewart T; Goodwin AC; Baylin SB; Woster PM; Casero RA Proc Natl Acad Sci U S A; 2007 May; 104(19):8023-8. PubMed ID: 17463086 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955 [TBL] [Abstract][Full Text] [Related]
8. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors. Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456 [TBL] [Abstract][Full Text] [Related]
9. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247 [TBL] [Abstract][Full Text] [Related]
10. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1. Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958 [TBL] [Abstract][Full Text] [Related]
11. Cyclic peptide inhibitors of lysine-specific demethylase 1 with improved potency identified by alanine scanning mutagenesis. Kumarasinghe IR; Woster PM Eur J Med Chem; 2018 Mar; 148():210-220. PubMed ID: 29459279 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors. Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia. Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576 [TBL] [Abstract][Full Text] [Related]
14. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933 [TBL] [Abstract][Full Text] [Related]
15. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation. Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189 [TBL] [Abstract][Full Text] [Related]
17. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil. Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070 [TBL] [Abstract][Full Text] [Related]
18. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029 [TBL] [Abstract][Full Text] [Related]
19. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Hosseini A; Minucci S Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367 [TBL] [Abstract][Full Text] [Related]
20. Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. Wu Y; Steinbergs N; Murray-Stewart T; Marton LJ; Casero RA Biochem J; 2012 Mar; 442(3):693-701. PubMed ID: 22132744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]